nodes	percent_of_prediction	percent_of_DWPC	metapath
Ergotamine—Bromocriptine—type 2 diabetes mellitus	0.357	1	CrCtD
Ergotamine—Ergoloid mesylate—Bromocriptine—type 2 diabetes mellitus	0.0671	0.269	CrCrCtD
Ergotamine—Dihydroergotamine—Bromocriptine—type 2 diabetes mellitus	0.0671	0.269	CrCrCtD
Ergotamine—ADRA2A—type 2 diabetes mellitus	0.0482	0.325	CbGaD
Ergotamine—HTR2C—type 2 diabetes mellitus	0.0444	0.299	CbGaD
Ergotamine—Methysergide—Bromocriptine—type 2 diabetes mellitus	0.0386	0.154	CrCrCtD
Ergotamine—Methylergometrine—Bromocriptine—type 2 diabetes mellitus	0.0386	0.154	CrCrCtD
Ergotamine—Ergonovine—Bromocriptine—type 2 diabetes mellitus	0.0386	0.154	CrCrCtD
Ergotamine—CYP1A2—type 2 diabetes mellitus	0.0335	0.226	CbGaD
Ergotamine—CYP3A4—type 2 diabetes mellitus	0.0222	0.15	CbGaD
Ergotamine—HTR1D—Bromocriptine—type 2 diabetes mellitus	0.0128	0.0753	CbGbCtD
Ergotamine—HTR2B—Bromocriptine—type 2 diabetes mellitus	0.0125	0.0737	CbGbCtD
Ergotamine—HTR1B—Bromocriptine—type 2 diabetes mellitus	0.0122	0.0722	CbGbCtD
Ergotamine—ADRA1D—Bromocriptine—type 2 diabetes mellitus	0.0122	0.0722	CbGbCtD
Ergotamine—ADRA2B—Bromocriptine—type 2 diabetes mellitus	0.0105	0.0622	CbGbCtD
Ergotamine—ADRA1B—Bromocriptine—type 2 diabetes mellitus	0.00891	0.0525	CbGbCtD
Ergotamine—HTR2C—Bromocriptine—type 2 diabetes mellitus	0.00813	0.048	CbGbCtD
Ergotamine—HTR1A—Bromocriptine—type 2 diabetes mellitus	0.00767	0.0452	CbGbCtD
Ergotamine—ADRA2A—Bromocriptine—type 2 diabetes mellitus	0.00733	0.0432	CbGbCtD
Ergotamine—HTR2A—Bromocriptine—type 2 diabetes mellitus	0.00733	0.0432	CbGbCtD
Ergotamine—ADRA1A—Bromocriptine—type 2 diabetes mellitus	0.00703	0.0414	CbGbCtD
Ergotamine—DRD2—Bromocriptine—type 2 diabetes mellitus	0.00675	0.0398	CbGbCtD
Ergotamine—ABCB1—Linagliptin—type 2 diabetes mellitus	0.00585	0.0345	CbGbCtD
Ergotamine—ABCB1—Sitagliptin—type 2 diabetes mellitus	0.00521	0.0307	CbGbCtD
Ergotamine—CYP1A2—Rosiglitazone—type 2 diabetes mellitus	0.00398	0.0234	CbGbCtD
Ergotamine—ABCB1—Chlorpropamide—type 2 diabetes mellitus	0.00377	0.0222	CbGbCtD
Ergotamine—CYP3A4—Linagliptin—type 2 diabetes mellitus	0.0035	0.0206	CbGbCtD
Ergotamine—CYP1A2—Irbesartan—type 2 diabetes mellitus	0.00313	0.0185	CbGbCtD
Ergotamine—CYP3A4—Sitagliptin—type 2 diabetes mellitus	0.00312	0.0184	CbGbCtD
Ergotamine—CYP1A2—Bromocriptine—type 2 diabetes mellitus	0.00296	0.0174	CbGbCtD
Ergotamine—CYP3A4—Glipizide—type 2 diabetes mellitus	0.00285	0.0168	CbGbCtD
Ergotamine—ABCB1—Bromocriptine—type 2 diabetes mellitus	0.00259	0.0153	CbGbCtD
Ergotamine—CYP3A4—Repaglinide—type 2 diabetes mellitus	0.0025	0.0147	CbGbCtD
Ergotamine—CYP3A4—Pioglitazone—type 2 diabetes mellitus	0.00226	0.0133	CbGbCtD
Ergotamine—CYP1A2—Losartan—type 2 diabetes mellitus	0.00202	0.0119	CbGbCtD
Ergotamine—ABCB1—Glyburide—type 2 diabetes mellitus	0.00193	0.0114	CbGbCtD
Ergotamine—ABCB1—Losartan—type 2 diabetes mellitus	0.00176	0.0104	CbGbCtD
Ergotamine—CYP3A4—Nateglinide—type 2 diabetes mellitus	0.00171	0.0101	CbGbCtD
Ergotamine—Ischaemia—Repaglinide—type 2 diabetes mellitus	0.00164	0.0567	CcSEcCtD
Ergotamine—CYP3A4—Irbesartan—type 2 diabetes mellitus	0.00164	0.00967	CbGbCtD
Ergotamine—CYP3A4—Orlistat—type 2 diabetes mellitus	0.00164	0.00967	CbGbCtD
Ergotamine—CYP3A4—Bromocriptine—type 2 diabetes mellitus	0.00155	0.00914	CbGbCtD
Ergotamine—Ischaemia—Rosiglitazone—type 2 diabetes mellitus	0.00155	0.0536	CcSEcCtD
Ergotamine—Ischaemia—Pioglitazone—type 2 diabetes mellitus	0.0013	0.0449	CcSEcCtD
Ergotamine—CYP3A4—Glyburide—type 2 diabetes mellitus	0.00116	0.00681	CbGbCtD
Ergotamine—Localised oedema—Irbesartan—type 2 diabetes mellitus	0.00107	0.037	CcSEcCtD
Ergotamine—CYP3A4—Losartan—type 2 diabetes mellitus	0.00106	0.00623	CbGbCtD
Ergotamine—SLC6A2—sympathetic nervous system—type 2 diabetes mellitus	0.000957	0.1	CbGeAlD
Ergotamine—HTR2A—arteriole—type 2 diabetes mellitus	0.000902	0.0944	CbGeAlD
Ergotamine—Peripheral coldness—Bromocriptine—type 2 diabetes mellitus	0.000875	0.0303	CcSEcCtD
Ergotamine—Emotional distress—Metformin—type 2 diabetes mellitus	0.000673	0.0233	CcSEcCtD
Ergotamine—SLC6A2—autonomic nervous system—type 2 diabetes mellitus	0.000643	0.0673	CbGeAlD
Ergotamine—HTR2A—sympathetic nervous system—type 2 diabetes mellitus	0.000575	0.0602	CbGeAlD
Ergotamine—Numbness—Bromocriptine—type 2 diabetes mellitus	0.000503	0.0174	CcSEcCtD
Ergotamine—Sensory loss—Bromocriptine—type 2 diabetes mellitus	0.000481	0.0166	CcSEcCtD
Ergotamine—HTR1B—artery—type 2 diabetes mellitus	0.000456	0.0477	CbGeAlD
Ergotamine—HTR1D—artery—type 2 diabetes mellitus	0.000441	0.0462	CbGeAlD
Ergotamine—Numbness—Gliclazide—type 2 diabetes mellitus	0.000413	0.0143	CcSEcCtD
Ergotamine—Sensory loss—Gliclazide—type 2 diabetes mellitus	0.000395	0.0136	CcSEcCtD
Ergotamine—HTR2A—autonomic nervous system—type 2 diabetes mellitus	0.000386	0.0404	CbGeAlD
Ergotamine—SLC6A2—nerve—type 2 diabetes mellitus	0.000362	0.0378	CbGeAlD
Ergotamine—HTR2A—hindlimb—type 2 diabetes mellitus	0.000357	0.0374	CbGeAlD
Ergotamine—DRD2—nerve—type 2 diabetes mellitus	0.00033	0.0345	CbGeAlD
Ergotamine—ADRA2A—peripheral nervous system—type 2 diabetes mellitus	0.000328	0.0343	CbGeAlD
Ergotamine—Numbness—Irbesartan—type 2 diabetes mellitus	0.000326	0.0113	CcSEcCtD
Ergotamine—Sensory loss—Irbesartan—type 2 diabetes mellitus	0.000312	0.0108	CcSEcCtD
Ergotamine—Vertigo—Tolazamide—type 2 diabetes mellitus	0.000293	0.0101	CcSEcCtD
Ergotamine—HTR2A—peripheral nervous system—type 2 diabetes mellitus	0.000279	0.0292	CbGeAlD
Ergotamine—Myalgia—Linagliptin—type 2 diabetes mellitus	0.000275	0.0095	CcSEcCtD
Ergotamine—Hypoaesthesia—Glipizide—type 2 diabetes mellitus	0.000247	0.00855	CcSEcCtD
Ergotamine—Musculoskeletal discomfort—Linagliptin—type 2 diabetes mellitus	0.00024	0.0083	CcSEcCtD
Ergotamine—Hypoaesthesia—Pioglitazone—type 2 diabetes mellitus	0.000237	0.00819	CcSEcCtD
Ergotamine—Bradycardia—Glimepiride—type 2 diabetes mellitus	0.000236	0.00816	CcSEcCtD
Ergotamine—Hypoaesthesia—Sitagliptin—type 2 diabetes mellitus	0.00023	0.00795	CcSEcCtD
Ergotamine—Hypertension—Repaglinide—type 2 diabetes mellitus	0.000226	0.00781	CcSEcCtD
Ergotamine—HTR2A—artery—type 2 diabetes mellitus	0.000219	0.0229	CbGeAlD
Ergotamine—HTR2A—nerve—type 2 diabetes mellitus	0.000217	0.0227	CbGeAlD
Ergotamine—Hypertension—Rosiglitazone—type 2 diabetes mellitus	0.000213	0.00738	CcSEcCtD
Ergotamine—Bradycardia—Bromocriptine—type 2 diabetes mellitus	0.000213	0.00736	CcSEcCtD
Ergotamine—Myalgia—Rosiglitazone—type 2 diabetes mellitus	0.00021	0.00727	CcSEcCtD
Ergotamine—Hypoaesthesia—Bromocriptine—type 2 diabetes mellitus	0.000208	0.0072	CcSEcCtD
Ergotamine—Pruritus—Tolbutamide—type 2 diabetes mellitus	0.000207	0.00716	CcSEcCtD
Ergotamine—ADRA1B—kidney—type 2 diabetes mellitus	0.000205	0.0215	CbGeAlD
Ergotamine—Musculoskeletal discomfort—Repaglinide—type 2 diabetes mellitus	0.000194	0.00672	CcSEcCtD
Ergotamine—Vertigo—Glipizide—type 2 diabetes mellitus	0.000194	0.00672	CcSEcCtD
Ergotamine—Nausea—Miglitol—type 2 diabetes mellitus	0.000193	0.00668	CcSEcCtD
Ergotamine—Paraesthesia—Repaglinide—type 2 diabetes mellitus	0.000192	0.00663	CcSEcCtD
Ergotamine—Asthenia—Tolazamide—type 2 diabetes mellitus	0.000191	0.0066	CcSEcCtD
Ergotamine—Pruritus—Chlorpropamide—type 2 diabetes mellitus	0.000188	0.00651	CcSEcCtD
Ergotamine—Pruritus—Tolazamide—type 2 diabetes mellitus	0.000188	0.00651	CcSEcCtD
Ergotamine—Hypertension—Glipizide—type 2 diabetes mellitus	0.000187	0.00646	CcSEcCtD
Ergotamine—Vertigo—Pioglitazone—type 2 diabetes mellitus	0.000186	0.00644	CcSEcCtD
Ergotamine—HTR2A—endothelium—type 2 diabetes mellitus	0.000185	0.0194	CbGeAlD
Ergotamine—Myalgia—Glipizide—type 2 diabetes mellitus	0.000184	0.00637	CcSEcCtD
Ergotamine—Musculoskeletal discomfort—Rosiglitazone—type 2 diabetes mellitus	0.000184	0.00635	CcSEcCtD
Ergotamine—Vertigo—Sitagliptin—type 2 diabetes mellitus	0.000181	0.00625	CcSEcCtD
Ergotamine—Hypertension—Pioglitazone—type 2 diabetes mellitus	0.000179	0.00619	CcSEcCtD
Ergotamine—Asthenia—Nateglinide—type 2 diabetes mellitus	0.000177	0.00612	CcSEcCtD
Ergotamine—Myalgia—Pioglitazone—type 2 diabetes mellitus	0.000177	0.0061	CcSEcCtD
Ergotamine—Bradycardia—Gliclazide—type 2 diabetes mellitus	0.000175	0.00605	CcSEcCtD
Ergotamine—Pruritus—Nateglinide—type 2 diabetes mellitus	0.000175	0.00603	CcSEcCtD
Ergotamine—Hypertension—Glimepiride—type 2 diabetes mellitus	0.000174	0.00603	CcSEcCtD
Ergotamine—Nausea—Tolbutamide—type 2 diabetes mellitus	0.000174	0.00601	CcSEcCtD
Ergotamine—Hypertension—Sitagliptin—type 2 diabetes mellitus	0.000174	0.00601	CcSEcCtD
Ergotamine—Dihydroergotamine—ADRA2A—type 2 diabetes mellitus	0.000172	0.127	CrCbGaD
Ergotamine—Myalgia—Sitagliptin—type 2 diabetes mellitus	0.000171	0.00592	CcSEcCtD
Ergotamine—Hypoaesthesia—Gliclazide—type 2 diabetes mellitus	0.000171	0.00591	CcSEcCtD
Ergotamine—Vomiting—Chlorpropamide—type 2 diabetes mellitus	0.000169	0.00585	CcSEcCtD
Ergotamine—Vertigo—Bromocriptine—type 2 diabetes mellitus	0.000164	0.00566	CcSEcCtD
Ergotamine—Vomiting—Acarbose—type 2 diabetes mellitus	0.000163	0.00562	CcSEcCtD
Ergotamine—Musculoskeletal discomfort—Glipizide—type 2 diabetes mellitus	0.000161	0.00556	CcSEcCtD
Ergotamine—Tachycardia—Glimepiride—type 2 diabetes mellitus	0.000161	0.00556	CcSEcCtD
Ergotamine—Paraesthesia—Glipizide—type 2 diabetes mellitus	0.000159	0.00548	CcSEcCtD
Ergotamine—HTR1B—cardiovascular system—type 2 diabetes mellitus	0.000158	0.0166	CbGeAlD
Ergotamine—Nausea—Chlorpropamide—type 2 diabetes mellitus	0.000158	0.00547	CcSEcCtD
Ergotamine—Nausea—Tolazamide—type 2 diabetes mellitus	0.000158	0.00547	CcSEcCtD
Ergotamine—Hypertension—Bromocriptine—type 2 diabetes mellitus	0.000157	0.00544	CcSEcCtD
Ergotamine—Vomiting—Nateglinide—type 2 diabetes mellitus	0.000157	0.00542	CcSEcCtD
Ergotamine—Musculoskeletal discomfort—Pioglitazone—type 2 diabetes mellitus	0.000154	0.00533	CcSEcCtD
Ergotamine—HTR1D—cardiovascular system—type 2 diabetes mellitus	0.000153	0.016	CbGeAlD
Ergotamine—Nausea—Acarbose—type 2 diabetes mellitus	0.000152	0.00525	CcSEcCtD
Ergotamine—Pain—Glipizide—type 2 diabetes mellitus	0.000151	0.00522	CcSEcCtD
Ergotamine—Pruritus—Repaglinide—type 2 diabetes mellitus	0.000151	0.00522	CcSEcCtD
Ergotamine—HTR1D—kidney—type 2 diabetes mellitus	0.00015	0.0157	CbGeAlD
Ergotamine—Musculoskeletal discomfort—Sitagliptin—type 2 diabetes mellitus	0.00015	0.00517	CcSEcCtD
Ergotamine—Paraesthesia—Glimepiride—type 2 diabetes mellitus	0.000148	0.00512	CcSEcCtD
Ergotamine—Nausea—Nateglinide—type 2 diabetes mellitus	0.000147	0.00506	CcSEcCtD
Ergotamine—Bradycardia—Metformin—type 2 diabetes mellitus	0.000146	0.00506	CcSEcCtD
Ergotamine—Tachycardia—Bromocriptine—type 2 diabetes mellitus	0.000145	0.00502	CcSEcCtD
Ergotamine—Asthenia—Rosiglitazone—type 2 diabetes mellitus	0.000145	0.005	CcSEcCtD
Ergotamine—Ergonovine—HTR2C—type 2 diabetes mellitus	0.000145	0.107	CrCbGaD
Ergotamine—Hypoaesthesia—Metformin—type 2 diabetes mellitus	0.000143	0.00494	CcSEcCtD
Ergotamine—Pruritus—Rosiglitazone—type 2 diabetes mellitus	0.000143	0.00493	CcSEcCtD
Ergotamine—HTR2B—cardiovascular system—type 2 diabetes mellitus	0.000143	0.0149	CbGeAlD
Ergotamine—Myalgia—Glyburide—type 2 diabetes mellitus	0.000142	0.0049	CcSEcCtD
Ergotamine—Pain—Sitagliptin—type 2 diabetes mellitus	0.000141	0.00486	CcSEcCtD
Ergotamine—Bradycardia—Irbesartan—type 2 diabetes mellitus	0.000138	0.00477	CcSEcCtD
Ergotamine—DRD2—retina—type 2 diabetes mellitus	0.000136	0.0143	CbGeAlD
Ergotamine—HTR2B—cortex of kidney—type 2 diabetes mellitus	0.000136	0.0142	CbGeAlD
Ergotamine—Vomiting—Repaglinide—type 2 diabetes mellitus	0.000136	0.00469	CcSEcCtD
Ergotamine—Hypoaesthesia—Irbesartan—type 2 diabetes mellitus	0.000135	0.00467	CcSEcCtD
Ergotamine—Paraesthesia—Bromocriptine—type 2 diabetes mellitus	0.000134	0.00462	CcSEcCtD
Ergotamine—Hypertension—Gliclazide—type 2 diabetes mellitus	0.000129	0.00446	CcSEcCtD
Ergotamine—HTR1A—cardiovascular system—type 2 diabetes mellitus	0.000128	0.0134	CbGeAlD
Ergotamine—Myalgia—Gliclazide—type 2 diabetes mellitus	0.000127	0.0044	CcSEcCtD
Ergotamine—Hypoaesthesia—Losartan—type 2 diabetes mellitus	0.000127	0.00439	CcSEcCtD
Ergotamine—Nausea—Repaglinide—type 2 diabetes mellitus	0.000127	0.00438	CcSEcCtD
Ergotamine—Asthenia—Glipizide—type 2 diabetes mellitus	0.000127	0.00438	CcSEcCtD
Ergotamine—Methylergometrine—HTR2C—type 2 diabetes mellitus	0.000126	0.0938	CrCbGaD
Ergotamine—HTR2B—adipose tissue—type 2 diabetes mellitus	0.000126	0.0132	CbGeAlD
Ergotamine—Pruritus—Glipizide—type 2 diabetes mellitus	0.000125	0.00432	CcSEcCtD
Ergotamine—Musculoskeletal discomfort—Glyburide—type 2 diabetes mellitus	0.000124	0.00428	CcSEcCtD
Ergotamine—ADRA2A—islet of Langerhans—type 2 diabetes mellitus	0.000124	0.013	CbGeAlD
Ergotamine—Vertigo—Valsartan—type 2 diabetes mellitus	0.000123	0.00427	CcSEcCtD
Ergotamine—Paraesthesia—Glyburide—type 2 diabetes mellitus	0.000122	0.00422	CcSEcCtD
Ergotamine—Vertigo—Orlistat—type 2 diabetes mellitus	0.000122	0.00422	CcSEcCtD
Ergotamine—Asthenia—Pioglitazone—type 2 diabetes mellitus	0.000121	0.0042	CcSEcCtD
Ergotamine—Nausea—Rosiglitazone—type 2 diabetes mellitus	0.00012	0.00414	CcSEcCtD
Ergotamine—Tachycardia—Gliclazide—type 2 diabetes mellitus	0.000119	0.00412	CcSEcCtD
Ergotamine—Asthenia—Glimepiride—type 2 diabetes mellitus	0.000118	0.00409	CcSEcCtD
Ergotamine—Asthenia—Sitagliptin—type 2 diabetes mellitus	0.000118	0.00407	CcSEcCtD
Ergotamine—ADRA1A—cardiovascular system—type 2 diabetes mellitus	0.000118	0.0123	CbGeAlD
Ergotamine—Myalgia—Valsartan—type 2 diabetes mellitus	0.000117	0.00404	CcSEcCtD
Ergotamine—Pruritus—Glimepiride—type 2 diabetes mellitus	0.000117	0.00403	CcSEcCtD
Ergotamine—Myalgia—Orlistat—type 2 diabetes mellitus	0.000116	0.004	CcSEcCtD
Ergotamine—Vomiting—Glipizide—type 2 diabetes mellitus	0.000112	0.00388	CcSEcCtD
Ergotamine—Musculoskeletal discomfort—Gliclazide—type 2 diabetes mellitus	0.000111	0.00384	CcSEcCtD
Ergotamine—Paraesthesia—Gliclazide—type 2 diabetes mellitus	0.00011	0.00379	CcSEcCtD
Ergotamine—Hypertension—Metformin—type 2 diabetes mellitus	0.000108	0.00373	CcSEcCtD
Ergotamine—Asthenia—Bromocriptine—type 2 diabetes mellitus	0.000107	0.00369	CcSEcCtD
Ergotamine—Myalgia—Metformin—type 2 diabetes mellitus	0.000107	0.00368	CcSEcCtD
Ergotamine—Vertigo—Irbesartan—type 2 diabetes mellitus	0.000106	0.00367	CcSEcCtD
Ergotamine—Methysergide—HTR2C—type 2 diabetes mellitus	0.000105	0.0782	CrCbGaD
Ergotamine—Nausea—Glipizide—type 2 diabetes mellitus	0.000105	0.00363	CcSEcCtD
Ergotamine—Vomiting—Glimepiride—type 2 diabetes mellitus	0.000105	0.00362	CcSEcCtD
Ergotamine—Vomiting—Sitagliptin—type 2 diabetes mellitus	0.000104	0.00361	CcSEcCtD
Ergotamine—Pain—Gliclazide—type 2 diabetes mellitus	0.000104	0.00361	CcSEcCtD
Ergotamine—Ergoloid mesylate—CYP3A4—type 2 diabetes mellitus	0.000104	0.0773	CrCbGaD
Ergotamine—ADRA1A—adipose tissue—type 2 diabetes mellitus	0.000104	0.0109	CbGeAlD
Ergotamine—Musculoskeletal discomfort—Valsartan—type 2 diabetes mellitus	0.000102	0.00353	CcSEcCtD
Ergotamine—Hypertension—Irbesartan—type 2 diabetes mellitus	0.000102	0.00352	CcSEcCtD
Ergotamine—Musculoskeletal discomfort—Orlistat—type 2 diabetes mellitus	0.000101	0.00349	CcSEcCtD
Ergotamine—Paraesthesia—Valsartan—type 2 diabetes mellitus	0.000101	0.00348	CcSEcCtD
Ergotamine—Myalgia—Irbesartan—type 2 diabetes mellitus	0.000101	0.00347	CcSEcCtD
Ergotamine—Vertigo—Losartan—type 2 diabetes mellitus	9.98e-05	0.00345	CcSEcCtD
Ergotamine—Paraesthesia—Orlistat—type 2 diabetes mellitus	9.95e-05	0.00344	CcSEcCtD
Ergotamine—Nausea—Glimepiride—type 2 diabetes mellitus	9.79e-05	0.00338	CcSEcCtD
Ergotamine—Nausea—Sitagliptin—type 2 diabetes mellitus	9.76e-05	0.00337	CcSEcCtD
Ergotamine—Asthenia—Glyburide—type 2 diabetes mellitus	9.75e-05	0.00337	CcSEcCtD
Ergotamine—Pruritus—Glyburide—type 2 diabetes mellitus	9.62e-05	0.00332	CcSEcCtD
Ergotamine—Pain—Orlistat—type 2 diabetes mellitus	9.48e-05	0.00328	CcSEcCtD
Ergotamine—Myalgia—Losartan—type 2 diabetes mellitus	9.46e-05	0.00327	CcSEcCtD
Ergotamine—Vomiting—Bromocriptine—type 2 diabetes mellitus	9.45e-05	0.00327	CcSEcCtD
Ergotamine—Tachycardia—Irbesartan—type 2 diabetes mellitus	9.41e-05	0.00325	CcSEcCtD
Ergotamine—Musculoskeletal discomfort—Metformin—type 2 diabetes mellitus	9.3e-05	0.00322	CcSEcCtD
Ergotamine—Lisuride—ADRA2A—type 2 diabetes mellitus	9.21e-05	0.0683	CrCbGaD
Ergotamine—Paraesthesia—Metformin—type 2 diabetes mellitus	9.17e-05	0.00317	CcSEcCtD
Ergotamine—HTR2A—retina—type 2 diabetes mellitus	9e-05	0.00942	CbGeAlD
Ergotamine—Tachycardia—Losartan—type 2 diabetes mellitus	8.85e-05	0.00306	CcSEcCtD
Ergotamine—Nausea—Bromocriptine—type 2 diabetes mellitus	8.83e-05	0.00305	CcSEcCtD
Ergotamine—Musculoskeletal discomfort—Irbesartan—type 2 diabetes mellitus	8.78e-05	0.00303	CcSEcCtD
Ergotamine—Asthenia—Gliclazide—type 2 diabetes mellitus	8.76e-05	0.00303	CcSEcCtD
Ergotamine—ADRA2A—pancreas—type 2 diabetes mellitus	8.71e-05	0.00911	CbGeAlD
Ergotamine—Paraesthesia—Irbesartan—type 2 diabetes mellitus	8.65e-05	0.00299	CcSEcCtD
Ergotamine—Vomiting—Glyburide—type 2 diabetes mellitus	8.64e-05	0.00299	CcSEcCtD
Ergotamine—Pruritus—Gliclazide—type 2 diabetes mellitus	8.64e-05	0.00298	CcSEcCtD
Ergotamine—Vertigo—Ramipril—type 2 diabetes mellitus	8.56e-05	0.00296	CcSEcCtD
Ergotamine—ADRA2A—cortex of kidney—type 2 diabetes mellitus	8.53e-05	0.00893	CbGeAlD
Ergotamine—Bromocriptine—ADRA2A—type 2 diabetes mellitus	8.53e-05	0.0633	CrCbGaD
Ergotamine—Lisuride—HTR2C—type 2 diabetes mellitus	8.48e-05	0.0629	CrCbGaD
Ergotamine—Musculoskeletal discomfort—Losartan—type 2 diabetes mellitus	8.26e-05	0.00286	CcSEcCtD
Ergotamine—Pain—Irbesartan—type 2 diabetes mellitus	8.24e-05	0.00285	CcSEcCtD
Ergotamine—Paraesthesia—Losartan—type 2 diabetes mellitus	8.14e-05	0.00281	CcSEcCtD
Ergotamine—Myalgia—Ramipril—type 2 diabetes mellitus	8.11e-05	0.0028	CcSEcCtD
Ergotamine—Nausea—Glyburide—type 2 diabetes mellitus	8.07e-05	0.00279	CcSEcCtD
Ergotamine—Asthenia—Valsartan—type 2 diabetes mellitus	8.05e-05	0.00278	CcSEcCtD
Ergotamine—Asthenia—Orlistat—type 2 diabetes mellitus	7.95e-05	0.00275	CcSEcCtD
Ergotamine—Pruritus—Valsartan—type 2 diabetes mellitus	7.93e-05	0.00274	CcSEcCtD
Ergotamine—ADRA2A—adipose tissue—type 2 diabetes mellitus	7.9e-05	0.00826	CbGeAlD
Ergotamine—Dihydroergotamine—CYP3A4—type 2 diabetes mellitus	7.9e-05	0.0586	CrCbGaD
Ergotamine—Bromocriptine—HTR2C—type 2 diabetes mellitus	7.85e-05	0.0583	CrCbGaD
Ergotamine—Pruritus—Orlistat—type 2 diabetes mellitus	7.84e-05	0.00271	CcSEcCtD
Ergotamine—Vomiting—Gliclazide—type 2 diabetes mellitus	7.76e-05	0.00268	CcSEcCtD
Ergotamine—Pain—Losartan—type 2 diabetes mellitus	7.76e-05	0.00268	CcSEcCtD
Ergotamine—HTR2A—cardiovascular system—type 2 diabetes mellitus	7.62e-05	0.00797	CbGeAlD
Ergotamine—Tachycardia—Ramipril—type 2 diabetes mellitus	7.59e-05	0.00262	CcSEcCtD
Ergotamine—HTR2A—kidney—type 2 diabetes mellitus	7.45e-05	0.0078	CbGeAlD
Ergotamine—Asthenia—Metformin—type 2 diabetes mellitus	7.33e-05	0.00253	CcSEcCtD
Ergotamine—ADRA1A—liver—type 2 diabetes mellitus	7.28e-05	0.00762	CbGeAlD
Ergotamine—Nausea—Gliclazide—type 2 diabetes mellitus	7.25e-05	0.00251	CcSEcCtD
Ergotamine—Pruritus—Metformin—type 2 diabetes mellitus	7.23e-05	0.0025	CcSEcCtD
Ergotamine—Ergonovine—CYP3A4—type 2 diabetes mellitus	7.22e-05	0.0536	CrCbGaD
Ergotamine—Vomiting—Valsartan—type 2 diabetes mellitus	7.13e-05	0.00246	CcSEcCtD
Ergotamine—Musculoskeletal discomfort—Ramipril—type 2 diabetes mellitus	7.09e-05	0.00245	CcSEcCtD
Ergotamine—Vomiting—Orlistat—type 2 diabetes mellitus	7.05e-05	0.00244	CcSEcCtD
Ergotamine—Paraesthesia—Ramipril—type 2 diabetes mellitus	6.98e-05	0.00241	CcSEcCtD
Ergotamine—Asthenia—Irbesartan—type 2 diabetes mellitus	6.91e-05	0.00239	CcSEcCtD
Ergotamine—ABCB1—islet of Langerhans—type 2 diabetes mellitus	6.9e-05	0.00722	CbGeAlD
Ergotamine—CYP3A4—kidney—type 2 diabetes mellitus	6.9e-05	0.00722	CbGeAlD
Ergotamine—Pruritus—Irbesartan—type 2 diabetes mellitus	6.82e-05	0.00236	CcSEcCtD
Ergotamine—Nausea—Valsartan—type 2 diabetes mellitus	6.66e-05	0.0023	CcSEcCtD
Ergotamine—Nausea—Orlistat—type 2 diabetes mellitus	6.58e-05	0.00228	CcSEcCtD
Ergotamine—Asthenia—Losartan—type 2 diabetes mellitus	6.51e-05	0.00225	CcSEcCtD
Ergotamine—Vomiting—Metformin—type 2 diabetes mellitus	6.49e-05	0.00224	CcSEcCtD
Ergotamine—Pruritus—Losartan—type 2 diabetes mellitus	6.42e-05	0.00222	CcSEcCtD
Ergotamine—Methylergometrine—CYP3A4—type 2 diabetes mellitus	6.31e-05	0.0468	CrCbGaD
Ergotamine—Vomiting—Irbesartan—type 2 diabetes mellitus	6.13e-05	0.00212	CcSEcCtD
Ergotamine—Nausea—Metformin—type 2 diabetes mellitus	6.07e-05	0.0021	CcSEcCtD
Ergotamine—CYP1A2—liver—type 2 diabetes mellitus	6.02e-05	0.0063	CbGeAlD
Ergotamine—Bromocriptine—CYP1A2—type 2 diabetes mellitus	5.93e-05	0.044	CrCbGaD
Ergotamine—ABCB1—retina—type 2 diabetes mellitus	5.9e-05	0.00617	CbGeAlD
Ergotamine—Vomiting—Losartan—type 2 diabetes mellitus	5.77e-05	0.00199	CcSEcCtD
Ergotamine—Nausea—Irbesartan—type 2 diabetes mellitus	5.72e-05	0.00198	CcSEcCtD
Ergotamine—Asthenia—Ramipril—type 2 diabetes mellitus	5.58e-05	0.00193	CcSEcCtD
Ergotamine—ABCB1—nephron tubule—type 2 diabetes mellitus	5.56e-05	0.00581	CbGeAlD
Ergotamine—Pruritus—Ramipril—type 2 diabetes mellitus	5.5e-05	0.0019	CcSEcCtD
Ergotamine—Nausea—Losartan—type 2 diabetes mellitus	5.39e-05	0.00186	CcSEcCtD
Ergotamine—ABCB1—cardiovascular system—type 2 diabetes mellitus	4.99e-05	0.00522	CbGeAlD
Ergotamine—Vomiting—Ramipril—type 2 diabetes mellitus	4.94e-05	0.00171	CcSEcCtD
Ergotamine—ABCB1—kidney—type 2 diabetes mellitus	4.88e-05	0.00511	CbGeAlD
Ergotamine—ABCB1—pancreas—type 2 diabetes mellitus	4.85e-05	0.00508	CbGeAlD
Ergotamine—ABCB1—cortex of kidney—type 2 diabetes mellitus	4.76e-05	0.00498	CbGeAlD
Ergotamine—HTR2A—liver—type 2 diabetes mellitus	4.71e-05	0.00493	CbGeAlD
Ergotamine—Nausea—Ramipril—type 2 diabetes mellitus	4.62e-05	0.0016	CcSEcCtD
Ergotamine—ABCB1—adipose tissue—type 2 diabetes mellitus	4.4e-05	0.0046	CbGeAlD
Ergotamine—CYP3A4—liver—type 2 diabetes mellitus	4.36e-05	0.00456	CbGeAlD
Ergotamine—Lisuride—CYP3A4—type 2 diabetes mellitus	4.23e-05	0.0314	CrCbGaD
Ergotamine—Bromocriptine—CYP3A4—type 2 diabetes mellitus	3.92e-05	0.0291	CrCbGaD
Ergotamine—ABCB1—liver—type 2 diabetes mellitus	3.09e-05	0.00323	CbGeAlD
Ergotamine—HTR2A—Signaling Pathways—INS—type 2 diabetes mellitus	7.97e-07	2.24e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—CCL2—type 2 diabetes mellitus	7.97e-07	2.24e-05	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—CD36—type 2 diabetes mellitus	7.96e-07	2.24e-05	CbGpPWpGaD
Ergotamine—ADRA1D—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	7.96e-07	2.24e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Metabolism—ALB—type 2 diabetes mellitus	7.95e-07	2.24e-05	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—NFKB1—type 2 diabetes mellitus	7.92e-07	2.23e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—RELA—type 2 diabetes mellitus	7.89e-07	2.22e-05	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—CASP3—type 2 diabetes mellitus	7.88e-07	2.22e-05	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—PPP2CA—type 2 diabetes mellitus	7.86e-07	2.21e-05	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—SRC—type 2 diabetes mellitus	7.86e-07	2.21e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—CCL2—type 2 diabetes mellitus	7.84e-07	2.2e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—IGF1—type 2 diabetes mellitus	7.84e-07	2.2e-05	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling by GPCR—IL6—type 2 diabetes mellitus	7.83e-07	2.2e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—AKT2—type 2 diabetes mellitus	7.83e-07	2.2e-05	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—VEGFA—type 2 diabetes mellitus	7.81e-07	2.2e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—INS—type 2 diabetes mellitus	7.8e-07	2.19e-05	CbGpPWpGaD
Ergotamine—HTR1F—Signaling Pathways—AKT1—type 2 diabetes mellitus	7.8e-07	2.19e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling by GPCR—EGFR—type 2 diabetes mellitus	7.8e-07	2.19e-05	CbGpPWpGaD
Ergotamine—HTR2B—Signaling by GPCR—AKT1—type 2 diabetes mellitus	7.76e-07	2.18e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—IGF1—type 2 diabetes mellitus	7.71e-07	2.17e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	7.71e-07	2.17e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—NOS3—type 2 diabetes mellitus	7.71e-07	2.17e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—AKT2—type 2 diabetes mellitus	7.7e-07	2.17e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—CCL2—type 2 diabetes mellitus	7.68e-07	2.16e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling by GPCR—EGFR—type 2 diabetes mellitus	7.67e-07	2.16e-05	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—VEGFA—type 2 diabetes mellitus	7.65e-07	2.15e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—RELA—type 2 diabetes mellitus	7.62e-07	2.14e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Metabolism—PIK3R1—type 2 diabetes mellitus	7.61e-07	2.14e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Metabolism—NOS3—type 2 diabetes mellitus	7.61e-07	2.14e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—PSMD6—type 2 diabetes mellitus	7.58e-07	2.13e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—SNAP25—type 2 diabetes mellitus	7.58e-07	2.13e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—SREBF1—type 2 diabetes mellitus	7.58e-07	2.13e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—RELA—type 2 diabetes mellitus	7.58e-07	2.13e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—IRS1—type 2 diabetes mellitus	7.57e-07	2.13e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—IGF1—type 2 diabetes mellitus	7.55e-07	2.12e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—AKT2—type 2 diabetes mellitus	7.54e-07	2.12e-05	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—MTHFR—type 2 diabetes mellitus	7.54e-07	2.12e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling by GPCR—EGFR—type 2 diabetes mellitus	7.51e-07	2.11e-05	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—MMP9—type 2 diabetes mellitus	7.45e-07	2.09e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—CTGF—type 2 diabetes mellitus	7.44e-07	2.09e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	7.44e-07	2.09e-05	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—PPARA—type 2 diabetes mellitus	7.4e-07	2.08e-05	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—SRC—type 2 diabetes mellitus	7.38e-07	2.07e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—HMGCR—type 2 diabetes mellitus	7.38e-07	2.07e-05	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—NFKB1—type 2 diabetes mellitus	7.37e-07	2.07e-05	CbGpPWpGaD
Ergotamine—HTR1E—Signaling Pathways—AKT1—type 2 diabetes mellitus	7.36e-07	2.07e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—PPARGC1A—type 2 diabetes mellitus	7.34e-07	2.06e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—GNB3—type 2 diabetes mellitus	7.34e-07	2.06e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	7.32e-07	2.06e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—HMOX1—type 2 diabetes mellitus	7.31e-07	2.05e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—RELA—type 2 diabetes mellitus	7.25e-07	2.04e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—INS—type 2 diabetes mellitus	7.25e-07	2.04e-05	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling by GPCR—AKT1—type 2 diabetes mellitus	7.22e-07	2.03e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—ADRA2A—type 2 diabetes mellitus	7.22e-07	2.03e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—CAT—type 2 diabetes mellitus	7.21e-07	2.03e-05	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—VEGFA—type 2 diabetes mellitus	7.19e-07	2.02e-05	CbGpPWpGaD
Ergotamine—ADRA2B—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	7.18e-07	2.02e-05	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—TGFB1—type 2 diabetes mellitus	7.17e-07	2.02e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	7.17e-07	2.02e-05	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—AGT—type 2 diabetes mellitus	7.16e-07	2.01e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—CCL2—type 2 diabetes mellitus	7.13e-07	2.01e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—CASP3—type 2 diabetes mellitus	7.12e-07	2e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	7.1e-07	2e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—NOS3—type 2 diabetes mellitus	7.1e-07	2e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling by GPCR—IL6—type 2 diabetes mellitus	7.07e-07	1.99e-05	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—CALM1—type 2 diabetes mellitus	7.04e-07	1.98e-05	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—EGFR—type 2 diabetes mellitus	7.03e-07	1.98e-05	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—TGFB1—type 2 diabetes mellitus	7.02e-07	1.97e-05	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—APOE—type 2 diabetes mellitus	7.02e-07	1.97e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—IGF1—type 2 diabetes mellitus	7.01e-07	1.97e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—AKT2—type 2 diabetes mellitus	7.01e-07	1.97e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—APOB—type 2 diabetes mellitus	7e-07	1.97e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	6.99e-07	1.96e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—NOS3—type 2 diabetes mellitus	6.99e-07	1.96e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling by GPCR—EGFR—type 2 diabetes mellitus	6.98e-07	1.96e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Metabolism—PTGS2—type 2 diabetes mellitus	6.96e-07	1.96e-05	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—APOA1—type 2 diabetes mellitus	6.94e-07	1.95e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—CYP2E1—type 2 diabetes mellitus	6.94e-07	1.95e-05	CbGpPWpGaD
Ergotamine—HTR1A—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	6.93e-07	1.95e-05	CbGpPWpGaD
Ergotamine—HTR2C—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	6.9e-07	1.94e-05	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—EGFR—type 2 diabetes mellitus	6.89e-07	1.94e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—CASP3—type 2 diabetes mellitus	6.87e-07	1.93e-05	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—SRC—type 2 diabetes mellitus	6.87e-07	1.93e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—CYP1A2—type 2 diabetes mellitus	6.86e-07	1.93e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—SLC2A1—type 2 diabetes mellitus	6.86e-07	1.93e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—NOS3—type 2 diabetes mellitus	6.84e-07	1.92e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	6.84e-07	1.92e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—CASP3—type 2 diabetes mellitus	6.83e-07	1.92e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling by GPCR—IL6—type 2 diabetes mellitus	6.82e-07	1.92e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—GSTM1—type 2 diabetes mellitus	6.81e-07	1.91e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling by GPCR—IL6—type 2 diabetes mellitus	6.79e-07	1.91e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—MMP9—type 2 diabetes mellitus	6.72e-07	1.89e-05	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—VEGFA—type 2 diabetes mellitus	6.69e-07	1.88e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—RELA—type 2 diabetes mellitus	6.69e-07	1.88e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—LPL—type 2 diabetes mellitus	6.69e-07	1.88e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	6.66e-07	1.87e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—NFKB1—type 2 diabetes mellitus	6.65e-07	1.87e-05	CbGpPWpGaD
Ergotamine—ADRA1B—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	6.6e-07	1.86e-05	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—TGFB1—type 2 diabetes mellitus	6.6e-07	1.85e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—RELA—type 2 diabetes mellitus	6.58e-07	1.85e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—SLC2A4—type 2 diabetes mellitus	6.58e-07	1.85e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—GCG—type 2 diabetes mellitus	6.58e-07	1.85e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—ADCY5—type 2 diabetes mellitus	6.54e-07	1.84e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—CASP3—type 2 diabetes mellitus	6.54e-07	1.84e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—GPX1—type 2 diabetes mellitus	6.52e-07	1.83e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling by GPCR—AKT1—type 2 diabetes mellitus	6.52e-07	1.83e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling by GPCR—IL6—type 2 diabetes mellitus	6.5e-07	1.83e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—MMP9—type 2 diabetes mellitus	6.49e-07	1.82e-05	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—EGFR—type 2 diabetes mellitus	6.47e-07	1.82e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—MMP9—type 2 diabetes mellitus	6.46e-07	1.82e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—RELA—type 2 diabetes mellitus	6.44e-07	1.81e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—NFKB1—type 2 diabetes mellitus	6.42e-07	1.81e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—NFKB1—type 2 diabetes mellitus	6.39e-07	1.8e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	6.36e-07	1.79e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—NOS3—type 2 diabetes mellitus	6.36e-07	1.79e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—CD36—type 2 diabetes mellitus	6.35e-07	1.79e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling by GPCR—AKT1—type 2 diabetes mellitus	6.3e-07	1.77e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—PPP2CA—type 2 diabetes mellitus	6.27e-07	1.76e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling by GPCR—AKT1—type 2 diabetes mellitus	6.26e-07	1.76e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—SRC—type 2 diabetes mellitus	6.2e-07	1.74e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—MMP9—type 2 diabetes mellitus	6.18e-07	1.74e-05	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—TGFB1—type 2 diabetes mellitus	6.14e-07	1.73e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—NFKB1—type 2 diabetes mellitus	6.12e-07	1.72e-05	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—PPARG—type 2 diabetes mellitus	6.11e-07	1.72e-05	CbGpPWpGaD
Ergotamine—DRD2—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	6.09e-07	1.71e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—VEGFA—type 2 diabetes mellitus	6.04e-07	1.7e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—CASP3—type 2 diabetes mellitus	6.03e-07	1.7e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—MTHFR—type 2 diabetes mellitus	6.02e-07	1.69e-05	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—EGFR—type 2 diabetes mellitus	6.02e-07	1.69e-05	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—INS—type 2 diabetes mellitus	6e-07	1.69e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling by GPCR—AKT1—type 2 diabetes mellitus	6e-07	1.69e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling by GPCR—IL6—type 2 diabetes mellitus	5.99e-07	1.68e-05	CbGpPWpGaD
Ergotamine—HTR2A—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	5.99e-07	1.68e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—RELA—type 2 diabetes mellitus	5.99e-07	1.68e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—SRC—type 2 diabetes mellitus	5.98e-07	1.68e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—SRC—type 2 diabetes mellitus	5.95e-07	1.67e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—CASP3—type 2 diabetes mellitus	5.93e-07	1.67e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—PPARA—type 2 diabetes mellitus	5.91e-07	1.66e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling by GPCR—IL6—type 2 diabetes mellitus	5.9e-07	1.66e-05	CbGpPWpGaD
Ergotamine—ADRA1A—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	5.86e-07	1.65e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—VEGFA—type 2 diabetes mellitus	5.83e-07	1.64e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—CASP3—type 2 diabetes mellitus	5.81e-07	1.63e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—VEGFA—type 2 diabetes mellitus	5.8e-07	1.63e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling by GPCR—IL6—type 2 diabetes mellitus	5.77e-07	1.62e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—AGT—type 2 diabetes mellitus	5.72e-07	1.61e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—SRC—type 2 diabetes mellitus	5.7e-07	1.6e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—MMP9—type 2 diabetes mellitus	5.7e-07	1.6e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—PPARGC1A—type 2 diabetes mellitus	5.67e-07	1.59e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—GNB3—type 2 diabetes mellitus	5.67e-07	1.59e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—HMOX1—type 2 diabetes mellitus	5.64e-07	1.59e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—NFKB1—type 2 diabetes mellitus	5.64e-07	1.59e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—CALM1—type 2 diabetes mellitus	5.62e-07	1.58e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—MMP9—type 2 diabetes mellitus	5.61e-07	1.58e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—APOE—type 2 diabetes mellitus	5.6e-07	1.58e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—CAT—type 2 diabetes mellitus	5.57e-07	1.56e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—VEGFA—type 2 diabetes mellitus	5.55e-07	1.56e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—NFKB1—type 2 diabetes mellitus	5.55e-07	1.56e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—TGFB1—type 2 diabetes mellitus	5.54e-07	1.56e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—APOA1—type 2 diabetes mellitus	5.54e-07	1.56e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling by GPCR—AKT1—type 2 diabetes mellitus	5.53e-07	1.55e-05	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—ALB—type 2 diabetes mellitus	5.5e-07	1.55e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—MMP9—type 2 diabetes mellitus	5.49e-07	1.54e-05	CbGpPWpGaD
Ergotamine—ADRA2A—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	5.45e-07	1.53e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling by GPCR—AKT1—type 2 diabetes mellitus	5.44e-07	1.53e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—EGFR—type 2 diabetes mellitus	5.43e-07	1.53e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—NFKB1—type 2 diabetes mellitus	5.43e-07	1.53e-05	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—IL6—type 2 diabetes mellitus	5.4e-07	1.52e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—APOB—type 2 diabetes mellitus	5.4e-07	1.52e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—CASP3—type 2 diabetes mellitus	5.4e-07	1.52e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling by GPCR—IL6—type 2 diabetes mellitus	5.36e-07	1.51e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—TGFB1—type 2 diabetes mellitus	5.35e-07	1.5e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling by GPCR—AKT1—type 2 diabetes mellitus	5.33e-07	1.5e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—TGFB1—type 2 diabetes mellitus	5.32e-07	1.5e-05	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—IL6—type 2 diabetes mellitus	5.29e-07	1.49e-05	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—PIK3R1—type 2 diabetes mellitus	5.26e-07	1.48e-05	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—NOS3—type 2 diabetes mellitus	5.26e-07	1.48e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—GSTM1—type 2 diabetes mellitus	5.26e-07	1.48e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—SRC—type 2 diabetes mellitus	5.25e-07	1.48e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—EGFR—type 2 diabetes mellitus	5.25e-07	1.47e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—EGFR—type 2 diabetes mellitus	5.22e-07	1.47e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—SRC—type 2 diabetes mellitus	5.17e-07	1.45e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—LPL—type 2 diabetes mellitus	5.16e-07	1.45e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—VEGFA—type 2 diabetes mellitus	5.12e-07	1.44e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—MMP9—type 2 diabetes mellitus	5.1e-07	1.43e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—TGFB1—type 2 diabetes mellitus	5.1e-07	1.43e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—SRC—type 2 diabetes mellitus	5.06e-07	1.42e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—ADCY5—type 2 diabetes mellitus	5.05e-07	1.42e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—NFKB1—type 2 diabetes mellitus	5.05e-07	1.42e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—VEGFA—type 2 diabetes mellitus	5.04e-07	1.42e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—GPX1—type 2 diabetes mellitus	5.03e-07	1.42e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—EGFR—type 2 diabetes mellitus	5e-07	1.4e-05	CbGpPWpGaD
Ergotamine—HTR1D—Signaling Pathways—AKT1—type 2 diabetes mellitus	4.99e-07	1.4e-05	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—IL6—type 2 diabetes mellitus	4.97e-07	1.4e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling by GPCR—AKT1—type 2 diabetes mellitus	4.95e-07	1.39e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—VEGFA—type 2 diabetes mellitus	4.93e-07	1.39e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—CD36—type 2 diabetes mellitus	4.9e-07	1.38e-05	CbGpPWpGaD
Ergotamine—HTR1B—Signaling Pathways—AKT1—type 2 diabetes mellitus	4.88e-07	1.37e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—PPARG—type 2 diabetes mellitus	4.88e-07	1.37e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—PPP2CA—type 2 diabetes mellitus	4.84e-07	1.36e-05	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—PTGS2—type 2 diabetes mellitus	4.81e-07	1.35e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—INS—type 2 diabetes mellitus	4.79e-07	1.35e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—SRC—type 2 diabetes mellitus	4.7e-07	1.32e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—TGFB1—type 2 diabetes mellitus	4.7e-07	1.32e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—MTHFR—type 2 diabetes mellitus	4.65e-07	1.31e-05	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—IL6—type 2 diabetes mellitus	4.63e-07	1.3e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—TGFB1—type 2 diabetes mellitus	4.62e-07	1.3e-05	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—EGFR—type 2 diabetes mellitus	4.61e-07	1.29e-05	CbGpPWpGaD
Ergotamine—HTR2B—Signaling Pathways—AKT1—type 2 diabetes mellitus	4.59e-07	1.29e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—VEGFA—type 2 diabetes mellitus	4.58e-07	1.29e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—PPARA—type 2 diabetes mellitus	4.56e-07	1.28e-05	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—EGFR—type 2 diabetes mellitus	4.53e-07	1.27e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—TGFB1—type 2 diabetes mellitus	4.53e-07	1.27e-05	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—EGFR—type 2 diabetes mellitus	4.44e-07	1.25e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—AGT—type 2 diabetes mellitus	4.41e-07	1.24e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—ALB—type 2 diabetes mellitus	4.39e-07	1.23e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—CALM1—type 2 diabetes mellitus	4.34e-07	1.22e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—APOE—type 2 diabetes mellitus	4.32e-07	1.22e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—APOA1—type 2 diabetes mellitus	4.28e-07	1.2e-05	CbGpPWpGaD
Ergotamine—ADRA1D—Signaling Pathways—AKT1—type 2 diabetes mellitus	4.27e-07	1.2e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—TGFB1—type 2 diabetes mellitus	4.21e-07	1.18e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—PIK3R1—type 2 diabetes mellitus	4.2e-07	1.18e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—NOS3—type 2 diabetes mellitus	4.2e-07	1.18e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—IL6—type 2 diabetes mellitus	4.18e-07	1.17e-05	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—EGFR—type 2 diabetes mellitus	4.12e-07	1.16e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—IL6—type 2 diabetes mellitus	4.03e-07	1.13e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—IL6—type 2 diabetes mellitus	4.01e-07	1.13e-05	CbGpPWpGaD
Ergotamine—ADRA2B—Signaling Pathways—AKT1—type 2 diabetes mellitus	3.85e-07	1.08e-05	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—PTGS2—type 2 diabetes mellitus	3.84e-07	1.08e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—IL6—type 2 diabetes mellitus	3.84e-07	1.08e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—PPARG—type 2 diabetes mellitus	3.77e-07	1.06e-05	CbGpPWpGaD
Ergotamine—HTR1A—Signaling Pathways—AKT1—type 2 diabetes mellitus	3.72e-07	1.05e-05	CbGpPWpGaD
Ergotamine—HTR2C—Signaling Pathways—AKT1—type 2 diabetes mellitus	3.7e-07	1.04e-05	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—INS—type 2 diabetes mellitus	3.69e-07	1.04e-05	CbGpPWpGaD
Ergotamine—ADRA1B—Signaling Pathways—AKT1—type 2 diabetes mellitus	3.54e-07	9.96e-06	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—IL6—type 2 diabetes mellitus	3.54e-07	9.95e-06	CbGpPWpGaD
Ergotamine—ADRA2A—Metabolism—AKT1—type 2 diabetes mellitus	3.5e-07	9.83e-06	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—IL6—type 2 diabetes mellitus	3.48e-07	9.79e-06	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—IL6—type 2 diabetes mellitus	3.41e-07	9.59e-06	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—ALB—type 2 diabetes mellitus	3.39e-07	9.52e-06	CbGpPWpGaD
Ergotamine—DRD2—Signaling Pathways—AKT1—type 2 diabetes mellitus	3.27e-07	9.18e-06	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—PIK3R1—type 2 diabetes mellitus	3.24e-07	9.11e-06	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—NOS3—type 2 diabetes mellitus	3.24e-07	9.11e-06	CbGpPWpGaD
Ergotamine—HTR2A—Signaling Pathways—AKT1—type 2 diabetes mellitus	3.21e-07	9.03e-06	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—IL6—type 2 diabetes mellitus	3.17e-07	8.91e-06	CbGpPWpGaD
Ergotamine—ADRA1A—Signaling Pathways—AKT1—type 2 diabetes mellitus	3.15e-07	8.84e-06	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—PTGS2—type 2 diabetes mellitus	2.96e-07	8.33e-06	CbGpPWpGaD
Ergotamine—ADRA2A—Signaling Pathways—AKT1—type 2 diabetes mellitus	2.92e-07	8.22e-06	CbGpPWpGaD
Ergotamine—ABCB1—Metabolism—AKT1—type 2 diabetes mellitus	2.42e-07	6.8e-06	CbGpPWpGaD
Ergotamine—CYP1A2—Metabolism—AKT1—type 2 diabetes mellitus	1.93e-07	5.43e-06	CbGpPWpGaD
Ergotamine—CYP3A4—Metabolism—AKT1—type 2 diabetes mellitus	1.49e-07	4.19e-06	CbGpPWpGaD
